• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

    3/21/24 8:31:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email

    Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch

    NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/

    NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)

    NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)

    Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDAQ:OSUR), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO, chairman of the board of directors, and chairman of the compensation committee. During his tenure as president and CEO, OraSure launched more FDA-cleared products, vastly expanded its sales, and developed and acquired more innovative products and services in its history.

    "I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board," said Dr. Tang. "For many years, the medical diagnostic industry has sought to bring in-home tests from the lab to regulatory approval and widespread consumer use. More than ever, NOWDx brings us all closer to fulfilling that vision for better, more accessible healthcare for everyone with its in-home test, with in-home results in minutes platform. I am honored to join a talented and engaged board of directors to assist a highly capable and experienced team led by CEO Rob Weigle."

    Prior to leading OraSure, Dr. Tang was president and CEO of the University City Science Center in Philadelphia, the mid-Atlantic region's premier innovation hub for life science companies. He also led Olympus America's Life Sciences Group, which included laboratory diagnostic, microscope, and translational research instruments. He earned his BS in Chemistry from the College of William & Mary, MS and Ph.D. in Chemical Engineering from Lehigh University, and an MBA for Executives from The Wharton School of Business at the University of Pennsylvania. In 2016, he was awarded a Doctor of Humane Letters (honoris causa) from Thomas Jefferson University (formerly Philadelphia University) and the Wagner Free Institute of Science.

    "We are extremely pleased to welcome Stephen as chairman of the board, and particularly fortunate for his expert understanding of the impact that at-home diagnostics can have in early detection of diseases. His deep knowledge in the diagnostics space and his impactful leadership at OraSure will be invaluable as we await FDA authorization for our first at-home test for syphilis and set up our entire product portfolio for commercial launch," said Rob Weigle, CEO of NOWDiagnostics. "In addition, his broad leadership experience in research and life sciences roles will help to guide our strategic vision of becoming the go-to choice for at-home and point-of-care diagnostics."

    Michele Colucci, founder and managing partner at DigitalDx, stated, "As a diagnostic fund, we at DigitalDx Ventures are incredibly excited to welcome Steve Tang to the NOWDx board of directors as its board chair. Very few professionals have the depth of experience in the diagnostic industry as Steve does, much less his level of expertise in the boardroom. His steady, supportive hand, collaborative approach, and revenue focus are exemplary and exactly what is needed to harness the incredible talent in the C-suite and complement the existing composition of the board. Boards are often like a puzzle, and in this context we'd say he's the perfect fit."

    "We are very much looking forward to the leadership and strategic direction that Stephen Tang will provide NOWDx," stated Jeremy Wilson, co-founder of NOWDx and co-managing partner of private equity firm NewRoad Capital Partners. "With his heavy-hitting expertise, he will position the company very well for future growth, while creating impact and innovation in the diagnostics industry."

    Dr. Tang currently serves on the Boards of Directors of several nonprofit organizations, including the William & Mary Foundation, Population Services International, Lehigh University, Team Pennsylvania Foundation, and Life Sciences Pennsylvania.

    About NOWDiagnostics (NOWDx)

    NOWDx develops and manufactures "Touch to Test" over-the-counter and point-of-care diagnostic tests that yield results in minutes. Its patented approach allows for virtually any immunological assay to be accurately performed onsite in one step using a tiny amount of capillary blood or, in some cases, saliva. NOWDx envisions a world where people have greater access to in-home testing with in-home results - in minutes. It is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.

    Please visit nowdx.com for more information or follow the company on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240321747977/en/

    Get the next $OSUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Gagliano Nancy J bought $4,982 worth of shares (2,100 units at $2.37), increasing direct ownership by 1% to 160,254 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:16:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

    Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and the "Company") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commi

    3/17/26 4:52:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    SEC Filings

    View All

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/17/26 5:29:43 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by OraSure Technologies Inc.

    10-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/9/26 4:29:14 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/5/26 4:15:16 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mcgrath Kenneth J

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/23/26 7:23:31 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Eglinton Manner Carrie

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/23/26 7:23:15 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anthony Michele Marie

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/19/26 4:05:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

    BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure"

    2/9/26 4:15:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Third Quarter 2025 Financial Results

    BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. "In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions," said Carrie

    11/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care